Location: Cambridge, MA
CIK: 0001400240 · Show all filings
Period: Q4 2020 (← Previous) (Next →)
Filing Date: Feb 16, 2021
Total Value: $5.493B (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | 30,871,524 | $3.225B | 58.7% | $16.43 | +515.6% | COM | 60770K107 |
| — | Sigilon Therapeutics Inc | 10,370,369 | $498M | 9.1% | $48.03 | — | COM | 82657L107 |
| — | Seres Therapeutics Inc | 14,673,973 | $360M | 6.5% | $8.55 | — | COM | 81750R102 |
| — | Rubius Therapeutics Inc | 38,296,526 | $291M | 5.3% | $24.00 | — | COM | 78116T103 |
| — | Evelo Biosciences Inc | 22,900,069 | $277M | 5.0% | $10.39 | — | COM | 299734103 |
| FHTX | Foghorn Therapeutics Inc | 12,674,120 | $257M | 4.7% | $19.16 | 0.0% | COM | 344174107 |
| DNLI | Denali Therapeutics Inc | 2,730,263 | $229M | 4.2% | $17.97 | +236.4% | COM | 24823R105 |
| KLDO | Kaleido Biosciences Inc | 19,360,710 | $176M | 3.2% | $13.03 | -37.1% | COM | 483347100 |
| — | Codiak Biosciences Inc | 2,607,303 | $84.22M | 1.5% | $32.30 | — | COM | 192010106 |
| — | Axcella Health Inc | 12,548,414 | $65.13M | 1.2% | $8.17 | — | COM | 05454B105 |
| — | Syros Pharmaceuticals Inc | 2,938,494 | $31.88M | 0.6% | $13.87 | — | COM | 87184Q107 |